BUZZ-PREVIEW: Amgen climbs ahead of earnings
AMGN•Amgen rises ahead of quarterly results
** Amgen AMGN.O shares up 2.2% on Tues ahead of qtrly results due after the closing bell, as investors watch for updates on its experimental weight-loss drug
** The biotechnology co is expected to report qtrly rev up 3% to $9.42 bln, while adj EPS is seen falling to $5.62 from $6.02, per LSEG
** AMGN has met or beaten EPS estimates in 7 of past 8 qtrs, with most recent miss in Q2 2024
** Co last week disclosed a material data breach involving patient health info, but has not yet found an impact on its operations
** Among the 37 analysts that cover Amgen Inc, the breakdown of recommendations is 16 "strong buy" or "buy," 18 "hold" and 3 "sell" or "strong sell" ratings
** Median price target of $360 is unchanged from a month ago
** Stock up 18.3% YTD vs 12.7% gain in Dow Industrials .DJI
** AMGN options imply a 4.9% swing for the shares, in either direction, by Fri; that is just below the 5.0% move the stock has logged on the day after results over the last 8-qtrs, according to according to Trade Alert
